Zydus Lifesciences beats estimates as North American sales drive surprise profit growth
Zydus Life reported a surprise profit rise today driven by strong North American sales. New drug launches helped the firm beat estimates despite industry pressure.
Insights:
Zydus Lifesciences Limited reported a consolidated third-quarter profit of 10.42 billion rupees for the period ended December 31, surpassing analyst estimates. The financial results, announced on February 9, 2026, exceeded the LSEG-compiled mean projection of 9.32 billion rupees. This performance was primarily driven by the introduction of new drug launches and robust growth within the North American market 
US.
US.The company’s overall revenue for the quarter rose by 30.3%, marking a significant shift in its near-term financial performance and market positioning. Within the United States generics market US, North American sales rose 16.4%, while India 
IN sales jumped nearly 13%. During the three-month period, Zydus Lifesciences Limited successfully launched four new products, contributing to the overall revenue surge.
US, North American sales rose 16.4%, while India IN sales jumped nearly 13%. During the three-month period, Zydus Lifesciences Limited successfully launched four new products, contributing to the overall revenue surge.
